Actively Recruiting

Age: 18Years +
All Genders
NCT06523608

Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease

Led by University Hospital Muenster · Updated on 2025-12-22

600

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this observational study is to predict the short- and long-term development of acute severe disease events, de novo hepatocarcinoma (HCC) and mortality in patients with advanced chronic liver disease using the M10S20 (Liver stiffness and Model for End-Stage Liver Disease Score \[MELD\] combined) and PLEASE (Platelet, Etiology, Age, Sex und Elastography) scores, as well as the validation of the cost-effectiveness of the algorithm. Patients in this study are randomly divided into two groups: * Control group: patients are examined according to the current clinical standard protocol (biannual follow-up). * Stratified surveillance program: * High-risk patients will receive an appointment for a hospital visit every 3 months. * Low-risk patients could receive an appointment in one year. When necessary, if decompensation develops or HCC occurs, patients could be followed-up more frequently.

CONDITIONS

Official Title

Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is hospitalized or outpatient with advanced chronic liver disease based on BAVENO criteria
  • Patient is 18 years or older
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Age under 18 years
  • Current malignancy except non-melanocytic skin cancer
  • Severe extra-hepatic diseases such as chronic renal failure requiring hemodialysis, severe heart disease (NYHA > II), severe chronic pulmonary disease (GOLD > III), severe neurological or psychiatric disorders
  • HIV positive status
  • Previous liver or other organ transplantation
  • Declines participation or cannot provide informed consent and has no legal surrogate decision maker with unlikely recovery of consent ability
  • Physician denies participation due to concerns about protocol adherence

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital Muenster

Münster, North Rhine-Westphalia, Germany, 48149

Actively Recruiting

Loading map...

Research Team

J

Jonel Trebicka, Prof. Dr. med.

CONTACT

J

Josune Cabello Calleja, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here